What did we learn from Big Pharma’s Q2 results?

Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different. From the rollout of AI to the oral GLP-1 battle between Novo Nordisk and Eli Lilly and new leadership at Sarepta and Sanofi, it feels like the opportunities and challenges for biopharma have never been greater.

In this week’s episode of "The Top Line," Fierce Pharma Senior Editor Fraiser Kansteiner and Fierce Biotech Senior Editor James Waldron share their takeaways from another whirlwind season of earnings calls. Alongside a Q2 scorecard breakdown, the Fierce editors discuss how several new CEOs are finding their footing, which drugs appear poised to cross the $1 billion sales threshold in 2026 and more.

To learn more about the topics in this episode: 

• Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas 
• Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
• Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow
• Sarepta’s new CEO Michael Severino faces critical milestones to prove growth

See omnystudio.com/listener for privacy information.